These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6344266)

  • 21. [Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
    Cavalli F; Beer M; Martz G; Jungi WF; Alberto P; Obrecht JP; Mermillod B; Brunner KW
    Schweiz Med Wochenschr; 1982 May; 112(22):774-83. PubMed ID: 7048518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adjuvant chemotherapy of breast cancer: an international review and the Swiss experience].
    Senn HJ
    Arch Geschwulstforsch; 1986; 56(6):425-33. PubMed ID: 3548640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial.
    Heuson JC; Sylvester R; Engelsman E
    Eur J Cancer (1965); 1980; Suppl 1():113-7. PubMed ID: 7032920
    [No Abstract]   [Full Text] [Related]  

  • 24. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
    Hartman AR; Fleming GF; Dillon JJ
    Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
    Ludwig Breast Cancer Study Group
    N Engl J Med; 1988 Sep; 319(11):677-83. PubMed ID: 2901037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-drug adjuvant chemotherapy for breast cancer.
    Carey RW; Sohier WD; Kaufman S; Weitzman SA; Kelley RM; Lew RA; Halpern E
    Cancer; 1979 Jul; 44(1):35-41. PubMed ID: 455262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current status in the treatment of breast cancer. II. Adjuvant chemotherapy, palliative polychemotherapy, chemoimmunotherapy--rating and results (author's transl)].
    Sauer H; Jehn U; Wilmanns W
    Klin Wochenschr; 1979 Sep; 57(18):921-6. PubMed ID: 91700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute.
    Ribeiro G; Palmer MK
    Br Med J (Clin Res Ed); 1983 Mar; 286(6368):827-30. PubMed ID: 6403101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of adjuvant therapy for breast cancer in the St. Louis Metropolitan area: 1976-1977.
    Van Amburg A; Oppenheim J; Presant CA; Oliver J
    Med Pediatr Oncol; 1980; 8(1):1-6. PubMed ID: 7003335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adjuvant chemotherapy of breast cancer].
    Rouëssé J; Menu-Brantôme A
    Presse Med; 1996 Nov; 25(35):1731-6. PubMed ID: 8977587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxic effects of early adjuvant chemotherapy for breast cancer.
    Ludwig Breast Cancer Study Group
    Lancet; 1983 Sep; 2(8349):542-4. PubMed ID: 6136695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy and hormonal therapy for operable breast cancer.
    Minor DR
    Front Radiat Ther Oncol; 1983; 17():115-23. PubMed ID: 6337077
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjuvant hormono-chemotherapy in operable breast cancer.
    Wilson R; Hanham IW; Mair G; Drake SR; Derry CD; McKenzie C; Stoll BA; Boesen E; Skeggs DB; Senanayake F
    Lancet; 1978 May; 1(8073):1101. PubMed ID: 77399
    [No Abstract]   [Full Text] [Related]  

  • 36. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.
    Cavalli F; Beer M; Martz G; Jungi WF; Alberto P; Obrecht JP; Mermillod B; Brunner KW
    Br Med J (Clin Res Ed); 1983 Jan; 286(6358):5-8. PubMed ID: 6401458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Status of adjuvant chemotherapy in patients with breast cancer.
    Ahmann DL
    Cancer; 1984 Feb; 53(3 Suppl):724-8. PubMed ID: 6362824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The current status of systemic adjuvant therapy in the management of primary breast cancer.
    Fisher B; Wolmark N
    Surg Clin North Am; 1981 Dec; 61(6):1347-60. PubMed ID: 7031938
    [No Abstract]   [Full Text] [Related]  

  • 39. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer.
    Rubens RD; Hayward JL; Knight RK; Bulbrook RD; Fentiman IS; Chaudary M; Howell A; Bush H; Crowther D; Sellwood RA; George WD; Howat JM
    Lancet; 1983 Apr; 1(8329):839-43. PubMed ID: 6132179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials.
    Himel HN; Liberati A; Gelber RD; Chalmers TC
    JAMA; 1986 Sep; 256(9):1148-59. PubMed ID: 3525880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.